Table 2 Immunoreactivity of NKX2.2, PDX-1 and CDX-2 in 109 well-differentiated neuroendocrine tumors
Site | Total = 109 | NKX2.2 + | PDX-1 + | CDX-2 + |
|---|---|---|---|---|
Rectum | 16 | 16 (100%) | 0 | 0 |
Colon | 5 | 5 (100%) | 0 | 3 (60%) |
Appendix | 22 | 22 (100%) | 7 (32%) | 22 (100%) |
Ileum | 12 | 11 (92%) | 1 (8%) | 12 (100%) |
Jejunum | 10 | 10 (100%) | 2 (20%) | 10 (100%) |
Duodenum | 4 | 4 (100%) | 3 (75%) | 3 (75%) |
Stomach | 12 | 2 (17%) | 0 | 0 |
Pancreas | 17 | 12 (71%) | 1 (6%) | 2 (11%) |
Lung | 11 | 0 | 0 | 0 |
Total GI-pancreas | 98 | 82 (84%) | 14 (14%) | 52 (53%) |